The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

GlaxoSmithKline Heart Disease Treatment Fails Late Stage Trial

Tue, 13th May 2014 06:56

LONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday its Phase III study for drug darapladib in the treatment of acute coronary syndrome failed to meet its primary endpoint of reducing major coronary events compared to a placebo when added to standard care.

The company said that the overall safety profile of the drug showed no major safety concerns.

Glaxo said that it would further analyse the data from the study to better understand its findings.

"We are disappointed that the outcome of this second phase III study with darapladib does not support a regulatory submission in atherosclerosis," said President of Research and Development Patrick Vallance in a statement.

Darapladib is not currently approved for use in any country.

Shares in Glaxo are not yet traded Tuesday. They last traded Monday at 1,617.90 pence.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2014 Alliance News Limited. All Rights Reserved.

Related Shares

More News
12 May 2024 14:50

French presidency: Amazon to announce new 1.2 bln euros investment in France

PARIS, May 12 (Reuters) - U.S. internet giant Amazon will announce a new 1.2 billion euros ($1.3 billion) investment in France, the French presidenc...

9 May 2024 15:51

UK dividends calendar - next 7 days

8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.